The serum concentration of the receptor activator of nuclear factor-kB ligand (RANKL), osteoprotegerin (OPG) and lipids profile in children with nephrotic syndrome

被引：0
|
作者：
Panczyk-Tomaszewska, M. [1 ]
Ziolkowska, H. [1 ]
Adamczuk, D. [1 ]
Gorska, E. [2 ]
Stelmaszczyk-Emmel, A. [2 ]
Roszkowska-Blaim, M. [1 ]
机构：
[1] Med Univ Warsaw, Dept Pediat & Nephrol, Warsaw, Poland
[2] Med Univ Warsaw, Dept Lab Diagnost & Clin lmuunol Dev Age, Warsaw, Poland
来源：
BONE | 2009年 / 45卷
关键词：
D O I：
10.1016/j.bone.2009.04.121
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [21] Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
    Kazemi-Sufi, Siamak
    Alipour, Shahriar
    Rabieepour, Masome
    Roshan-Milani, Shiva
    Naderi, Roya
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [22] Elevated serum soluble receptor activator of nuclear factor kB ligand (RANKL) concentration in ankylosing spondylitis.
    Lee, SH
    Kim, HR
    Hong, JH
    Min, DJ
    Seo, YI
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S391 - S392
  • [23] Study of the osteoprotegerin/receptor activator of nuclear factor-kB ligand system association with inflammation and atherosclerosis in systemic sclerosis
    Gamal, Rania M.
    Gamal, Walid M.
    Ghandour, Abeer M.
    Abozaid, Hanan Sayed M.
    Mohamed, Mona Embarek
    Emad, Yasser
    Galeel, Ahmed Abdel
    IMMUNOLOGICAL INVESTIGATIONS, 2018, 47 (03) : 241 - 250
  • [24] Osteoprotegerin (OPG) and receptor activator of nuclear factor kappab ligand (RANKL) in pediatric chronic kidney disease (CKD)
    van Husen, M.
    Fischer, A. K.
    Klaassen, I.
    Lehnhardt, A.
    Moeller, K.
    Mueller-Wiefel, D. E.
    Kemper, M. J.
    BONE, 2009, 45 : S65 - S65
  • [25] Osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) in the serum of healthy adults
    Jung, K
    Lein, M
    Von Hösslin, K
    Grosse, A
    Roth, S
    Possinger, K
    Lüftner, D
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (03): : 177 - 181
  • [26] Study of the serum level of receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) in patients with rheumatoid arthritis
    Wagdy, E.
    Moghazy, T. F.
    Ragab, W. S.
    Aref, T. Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 372 - 372
  • [27] SERUM LEVELS OF OSTEOPROTEGERIN, RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KB LIGAND (RANKL) AND OTHER BIOCHEMICAL MARKERS OF BONE TURNOVER IN CHILDREN WITH CHRONIC KIDNEY DISEASE
    Siomou, E.
    Challa, A.
    Printza, N.
    Serbis, A.
    Petropoulou, F.
    Mitsioni, A.
    Papachristou, F.
    Stefanidis, C. J.
    PEDIATRIC NEPHROLOGY, 2009, 24 (09) : 1881 - 1882
  • [28] RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B LIGAND (RANKL)/RANK AND OSTEOPROTEGERIN (OPG) PATHWAY ACTIVATION IN SJOGREN'S SYNDROME
    Skarlis, Charalampos
    Palli, Eleni
    Nezos, Adrianos
    Mavragani, Clio
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1549 - 1549
  • [29] Serum concentrations of proapoptotic cytokines TNF-related apoptosis-inducing ligand (TRAIL), osteoprotegerin (OPG) and receptor activator of nuclear factor kB ligand (RANKL) in children with autoimmune hypothyroidism and autoimmune hyperthyroidism
    Niedziela, Marek
    Mikos, Hanna
    Mikos, Marcin
    HORMONE RESEARCH, 2009, 72 : 216 - 216
  • [30] Expression Profile of Receptor Activator of Nuclear-κB (RANK), RANK Ligand (RANKL) and Osteoprotegerin (OPG) in Breast Cancer
    Owen, Sioned
    Ye, Lin
    Sanders, Andrew J.
    Mason, Malcolm D.
    Jiang, Wen G.
    ANTICANCER RESEARCH, 2013, 33 (01) : 199 - 206
12345